The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients

Background The role of nipple discharge cytology (NDc) in the surgical management of breast cancer patients is unclear. We aimed: (i) to evaluate the effect of malignant NDc on the surgical approach to the nipple-areola complex, and (ii) to verify the association between malignant NDc and nipple malignancy. Methods We retrospectively analyzed a case series of 139 patients with NDc who underwent breast surgery. The clinical and histological findings, types of surgery with emphasis on nipple-areola complex amputation, immunohistochemical phenotypes of the carcinomas and measurements of the tumor-nipple distance were recorded. Additionally, in patients who showed HER2-positive lesions on definitive surgery, we evaluated the HER2 immunocytochemistry of the NDc smears. Results Thirty-two malignant and 107 benign/borderline NDc diagnoses were identified. All 32 malignant-NDc cases were histologically confirmed as malignant. Thirty borderline/benign-NDc cases were histologically diagnosed as malignant (sensitivity 58%). The majority of the patients with malignant NDc were treated with nipple-areola complex amputations in both the mastectomy and conservative surgery groups (P<0.001, χ251.77). Nipple involvement was strongly associated with HER2-positive ductal carcinoma in-situ (P<0.001, χ211.98). HER2 immunocytochemistry on the NDc revealed a 100% correlation with the immunocytochemistry performed on the surgical tissues. Conclusions Malignant NDc influenced surgical management. The association of malignant NDc with nipple involvement is highly related to ductal carcinoma in-situ with HER2 overexpression. In case of HER2 positive NDc, nipple-areola complex involvement is more likely than in HER2 negative cases.

[1]  R. Ponzone,et al.  MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. , 2015, European journal of cancer.

[2]  E. Baracat,et al.  Improved frozen section examination of the retroareolar margin for prediction of nipple involvement in breast cancer. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  M. Dowsett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Sismondi,et al.  Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. , 2012, European journal of cancer.

[5]  X. Zha,et al.  Bloody nipple discharge is a predictor of breast cancer risk: a meta-analysis , 2012, Breast Cancer Research and Treatment.

[6]  D. Hicks,et al.  Predictors of Nipple–Areolar Complex Involvement by Breast Carcinoma: Histopathologic Analysis of 787 Consecutive Therapeutic Mastectomy Specimens , 2011, Annals of Surgical Oncology.

[7]  Liya Fu,et al.  Nipple Involvement in Breast Cancer: Retrospective Analysis of 2323 Consecutive Mastectomy Specimens , 2011, International journal of surgical pathology.

[8]  J. Butler,et al.  Nipple discharge and the efficacy of duct cytology in evaluating breast cancer risk. , 2010, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[9]  S. Paepke,et al.  Nipple-Sparing Mastectomy – Extended Indications and Limitations , 2010, Breast Care.

[10]  H. El-Daly,et al.  Evaluation of Nipple Discharge Cytology and Diagnostic Value of Red Blood Cells in Cases with Negative Cytology , 2010, Acta Cytologica.

[11]  E. Elkin,et al.  Lessons learned from 416 cases of nipple discharge of the breast. , 2010, American journal of surgery.

[12]  R. Milanović,et al.  Intraoperative imprint cytological assessment of the subareolar tissue of the nipple areola complex (NAC). , 2010, Collegium antropologicum.

[13]  Barbara L. Smith,et al.  Nipple‐sparing mastectomy , 2010, The British journal of surgery.

[14]  T. Tot,et al.  Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study , 2010, Modern Pathology.

[15]  S. Zervoudis,et al.  Nipple Discharge Screening , 2010, Women's health.

[16]  Barbara L. Smith,et al.  Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Strobbe,et al.  The diagnostic value of nipple discharge cytology in 618 consecutive patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  Barbara L. Smith,et al.  Development and validation of a model predictive of occult nipple involvement in women undergoing mastectomy , 2008, The British journal of surgery.

[19]  Ming Yang,et al.  [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma]. , 2008, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[20]  P. Karstaedt,et al.  Navigating murky waters: a modern treatment algorithm for nipple discharge. , 2007, American journal of surgery.

[21]  A. Luini,et al.  Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? , 2006, Journal of the American College of Surgeons.

[22]  J. Crowe,et al.  Identification of breast cancer in patients with pathologic nipple discharge: does ductoscopy predict malignancy? , 2006, American journal of surgery.

[23]  M. Freeman,et al.  Applicability of the Nipple-Areola Complex-Sparing Mastectomy: A Prediction Model Using Mammography to Estimate Risk of Nipple-Areola Complex Involvement in Breast Cancer Patients , 2006, Annals of plastic surgery.

[24]  M. Petrovecki,et al.  Nipple–Areola Complex Preservation: Predictive Factors of Neoplastic Nipple–Areola Complex Invasion , 2005, Annals of plastic surgery.

[25]  B. Pritt,et al.  Diagnostic value of nipple cytology , 2004, Cancer.

[26]  S. Singletary,et al.  Feasibility of breast‐conserving surgery for patients with breast carcinoma associated with nipple discharge , 2004, Cancer.

[27]  Wen-ying Lee,et al.  Cytology of abnormal nipple discharge: a cyto‐histological correlation , 2003, Cytopathology : official journal of the British Society for Clinical Cytology.

[28]  R. L. Bauer,et al.  Ductal carcinoma in situ-associated nipple discharge: A clinical marker for locally extensive disease , 1998, Annals of Surgical Oncology.

[29]  S. Kılıçturgay,et al.  Management of nipple discharge. , 1994, Journal of the American College of Surgeons.

[30]  H. Roels,et al.  Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast , 1994, Histopathology.

[31]  M. Wick,et al.  Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. , 1991, American journal of clinical pathology.

[32]  T. Löning,et al.  Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. , 1990, The American journal of pathology.

[33]  H. Leis Management of nipple discharge , 1989, World Journal of Surgery.

[34]  D. Barnes,et al.  An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple , 1989, Histopathology.

[35]  V. Sacchini,et al.  Nipple-Sparing Mastectomy , 2019, Oncoplastic and Reconstructive Breast Surgery.

[36]  P. Cheung,et al.  Nipple Preservation in Breast Cancer Associated with Nipple Discharge , 2016, World Journal of Surgery.

[37]  G. Fernandes,et al.  What is the diagnostic value of nipple discharge cytology and galactography in detecting duct pathology? , 2009, European journal of gynaecological oncology.

[38]  Facs Rache M. Simmons MD,et al.  Analysis of nipple/areolar involvement with mastectomy: Can the areola be preserved? , 2007, Annals of Surgical Oncology.